[go: up one dir, main page]

AR121226A1 - Compuestos y usos de estos - Google Patents

Compuestos y usos de estos

Info

Publication number
AR121226A1
AR121226A1 ARP210100245A ARP210100245A AR121226A1 AR 121226 A1 AR121226 A1 AR 121226A1 AR P210100245 A ARP210100245 A AR P210100245A AR P210100245 A ARP210100245 A AR P210100245A AR 121226 A1 AR121226 A1 AR 121226A1
Authority
AR
Argentina
Prior art keywords
compounds
compound
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP210100245A
Other languages
English (en)
Inventor
Rishi G Vaswani
David S Huang
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of AR121226A1 publication Critical patent/AR121226A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1), o una sal farmacéuticamente aceptable de este.
ARP210100245A 2020-01-29 2021-01-29 Compuestos y usos de estos AR121226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062967359P 2020-01-29 2020-01-29

Publications (1)

Publication Number Publication Date
AR121226A1 true AR121226A1 (es) 2022-04-27

Family

ID=76970694

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100245A AR121226A1 (es) 2020-01-29 2021-01-29 Compuestos y usos de estos

Country Status (17)

Country Link
US (3) US11485732B2 (es)
EP (1) EP4096664A4 (es)
JP (1) JP7561195B2 (es)
KR (1) KR20220133258A (es)
CN (1) CN115023226A (es)
AR (1) AR121226A1 (es)
AU (1) AU2021213811A1 (es)
BR (1) BR112022015004A2 (es)
CA (1) CA3167275A1 (es)
CO (1) CO2022010547A2 (es)
IL (1) IL295100A (es)
MX (1) MX2022009309A (es)
PH (1) PH12022551937A1 (es)
TW (1) TWI859406B (es)
UA (1) UA129728C2 (es)
WO (1) WO2021155262A1 (es)
ZA (1) ZA202207804B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
WO2020160198A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3917529A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) * 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
MX2022009309A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de los mismos.
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CN115867314A (zh) * 2020-05-20 2023-03-28 福宏治疗公司 治疗癌症的方法
US20240158387A1 (en) * 2021-03-09 2024-05-16 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
JP2024511383A (ja) * 2021-03-19 2024-03-13 フォグホーン セラピューティクス インコーポレイテッド Ｂｒｇ１及びｂｒｍの酵素活性の阻害剤の治療レジメン
EP4376886A4 (en) * 2021-07-29 2025-05-14 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196560A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer
US20250339441A1 (en) * 2022-04-08 2025-11-06 Foghorn Therapeutics Inc. Methods of treating cancer
KR20250024923A (ko) * 2022-05-11 2025-02-20 포그혼 쎄라퓨틱스 인크. 화합물 및 그의 용도
WO2024125543A1 (zh) * 2022-12-16 2024-06-20 苏州科睿思制药有限公司 达洛色替的晶型及其制备方法和用途
WO2024249769A2 (en) * 2023-06-02 2024-12-05 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2025042981A2 (en) * 2023-08-21 2025-02-27 Ideaya Biosciences, Inc. Pharmaceutical compositions comprising a pkc inhibitor
WO2025080769A1 (en) * 2023-10-10 2025-04-17 Foghorn Therapeutics Inc. Methods of treating cancer

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2788341A (en) 1953-03-06 1957-04-09 Ciba Pharm Prod Inc Process for the manufacture of aminoacyl compounds
US3624097A (en) 1969-07-22 1971-11-30 Warner Lambert Co N-pyridine 5-aminooxazoles
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
FR2568880B1 (fr) 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
DK0516069T3 (da) 1991-05-31 1996-05-13 Sumitomo Pharma Leukotrien B4-antagonister
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US6180612B1 (en) 1997-10-31 2001-01-30 The University Of Virginia Patent Foundation Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
ES2257051T3 (es) 1998-05-27 2006-07-16 Avigen, Inc. Administracion potenciada por conveccion de vectores aav que codifican aadc.
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
AU6229699A (en) 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
WO2000059888A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
BR0009539A (pt) 1999-04-02 2006-06-06 Neurogen Corp composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
US7205103B2 (en) 2000-02-11 2007-04-17 The Salk Institute For Biological Studies Method of regulating transcription in a cell
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US6716622B2 (en) 2000-07-18 2004-04-06 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US20030027335A1 (en) 2000-09-07 2003-02-06 Ruley H. Earl Genome engineering by cell-permeable DNA site-specific recombinases
US6911311B2 (en) 2001-01-04 2005-06-28 Myriad Genetics, Inc. Method of detecting protein-protein interactions
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
JP2003077651A (ja) 2001-08-30 2003-03-14 Sharp Corp 有機エレクトロルミネッセンス素子の製造方法
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
US20050079512A1 (en) 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
US20040216178A1 (en) 2003-03-03 2004-10-28 Jones Stephen N Regulation of mdm2 function
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
RU2006117304A (ru) 2003-10-20 2007-12-10 Нсджин А/С (Dk) Генная терапия болезни паркинсона iv vivo
JP2007527240A (ja) 2004-03-01 2007-09-27 マサチューセッツ インスティテュート オブ テクノロジー アレルギー性鼻炎および喘息のためのＲＮＡｉベースの治療
WO2005112620A2 (en) 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
AU2005261487A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
ATE421962T1 (de) 2004-11-11 2009-02-15 Ferrer Int Imidazoä1,2-aüpyridinverbindungen, zusammensetzungen, anwendungen und verfahren, die damit in zusammenhang stehen
WO2006070806A1 (ja) 2004-12-28 2006-07-06 Taiho Pharmaceutical Co., Ltd. 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物
US20070105181A1 (en) 2005-05-04 2007-05-10 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated pdroteins
CN101528226B (zh) 2006-08-24 2012-01-11 澳大利亚核科学技术组织 靶向外周苯二氮卓受体的氟化配体
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8518960B2 (en) 2007-05-23 2013-08-27 Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
ES2392482T3 (es) 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
PE20110105A1 (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1
EP2393480A1 (en) 2009-02-05 2011-12-14 Targeted Delivery Technologies Limited Methods of reducing the proliferation and viability of microbial agents
CA2793311C (en) 2010-03-17 2019-01-15 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
CA2797291C (en) 2010-04-22 2020-08-11 British Columbia Cancer Agency Branch Novel biomarkers and targets for ovarian carcinoma
WO2012015937A2 (en) 2010-07-29 2012-02-02 The Regents Of The University Of Michigan Parp1 targeted therapy
US9072052B2 (en) 2010-08-09 2015-06-30 Blackberry Limited Communication system providing context-based mobile wireless communications device power consumption management and related methods
US9656959B2 (en) 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EA201301173A1 (ru) 2011-04-15 2015-08-31 Дженелюкс Корпорейшн Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
US8945861B2 (en) 2011-08-03 2015-02-03 Pierce Biotechnology, Inc. Methods for isotopically labeling biomolecules using mammalian cell-free extracts
JP6175078B2 (ja) 2012-02-01 2017-08-02 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 新規のシステインプロテアーゼ阻害剤及びその使用
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US20160046961A1 (en) 2012-05-25 2016-02-18 Emmanuelle Charpentier Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
DK2898075T3 (en) 2012-12-12 2016-06-27 Broad Inst Inc CONSTRUCTION AND OPTIMIZATION OF IMPROVED SYSTEMS, PROCEDURES AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
AU2014237198A1 (en) 2013-03-15 2015-11-05 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
ES2900301T3 (es) 2013-03-15 2022-03-16 Novartis Ag Biomarcadores asociados con la inhibición de BRM
US10976320B2 (en) 2013-05-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for identifying and treating cancer patients
WO2015002230A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 アミド化合物
JPWO2015005473A1 (ja) 2013-07-12 2017-03-02 国立研究開発法人国立がん研究センター がんの治療への応答性を予測する方法
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
WO2015046193A1 (ja) * 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
BR112016015449A8 (pt) 2013-12-30 2020-06-09 Lifesci Pharmaceuticals Inc compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
US9919998B2 (en) 2014-02-06 2018-03-20 Rutgers, The State University Of New Jersey Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides
GB201402771D0 (en) 2014-02-17 2014-04-02 Isis Innovation Biomarker & therapeutic target for sarcoma
HRP20201153T1 (hr) 2014-08-08 2021-01-22 The Board Of Trustees Of The Leland Stanford Junior University Pd-1 sredstva visokog afiniteta i načini uporabe
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9636323B2 (en) 2014-10-27 2017-05-02 Baylor College Of Medicine Method of treating cancer that overexpresses TopBP1
CN104530013B (zh) 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
US9546296B2 (en) 2014-12-15 2017-01-17 Ppg Industries Ohio, Inc. Coating compositions, coatings and methods for sound and vibration damping and water resistance
US9932340B2 (en) 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016160718A1 (en) 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
US20180140722A1 (en) 2015-04-06 2018-05-24 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of heart failure
EP3108883A1 (en) 2015-06-22 2016-12-28 Fundació Institut de Recerca Biomèdica de Bellvitge Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
IL260469B2 (en) 2016-01-08 2025-10-01 The Institute Of Cancer Res Royal Cancer Hospital Inhibitors of ataxia telangiectasia and rad3-related protein kinase (atr) mutations for use in cancer treatment methods
KR20180114202A (ko) 2016-02-26 2018-10-17 아지오스 파마슈티컬스 아이엔씨. 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제
CN108290708A (zh) 2016-02-29 2018-07-17 富士达株式会社 信息提供装置、电梯群管理系统以及电梯系统
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
EP3579847A4 (en) 2017-02-08 2020-12-09 Dana Farber Cancer Institute, Inc. MODULAR DEGRADATION OF ENDOGENOUS PROTEIN WITH HETEROBIFUNCTIONAL COMPOUNDS
JP2020508995A (ja) 2017-02-28 2020-03-26 エピザイム，インコーポレイティド 癌の処置のためのｓｍａｒｃａ２の阻害
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
US11453647B2 (en) 2017-08-21 2022-09-27 Merck Patent Gmbh Benzimidazole derivatives as adenosine receptor antagonists
WO2019040098A1 (en) 2017-08-21 2019-02-28 Dana-Farber Cancer Institute, Inc. METHODS OF MODULATING THE INTERACTION BETWEEN BAF COMPLEXES AND EWS-FLI1
ES2963417T3 (es) 2018-01-15 2024-03-27 UCB Biopharma SRL Derivados de imidazol condensados como moduladores de IL-17
EP3740482A1 (en) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. New methionine metabolic pathway inhibitors
JP2021512167A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 障害を治療するための方法及び化合物
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
WO2019226915A1 (en) 2018-05-25 2019-11-28 Rutgers, The State University Of New Jersey Antibacterial agents: dual-targeted rna polymerase inhibitors
US20210260171A1 (en) 2018-06-21 2021-08-26 Foghorn Therapeutics Inc. Methods of treating disorders
US20210251988A1 (en) 2018-06-21 2021-08-19 Foghorn Therapeutics Inc. Methods of treating disorders
HRP20230477T1 (hr) 2018-08-17 2023-07-21 Novartis Ag Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze
WO2020041756A1 (en) 2018-08-23 2020-02-27 Foghorn Therapeutics Inc. Methods of treating cancer
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US20210388040A1 (en) 2018-10-17 2021-12-16 Dana-Farber Cancer Institute, Inc. Non-canonical swi/snf complex and uses thereof
JP2022508155A (ja) 2018-11-21 2022-01-19 フォグホーン セラピューティクス インコーポレイテッド がんを治療する方法
AU2019410261B2 (en) 2018-12-19 2025-10-02 Leo Pharma A/S Amino-acid anilides as small molecule modulators of IL-17
WO2020160180A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
EP3917529A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
MX2022002244A (es) 2019-09-12 2022-03-22 Aurigene Discovery Tech Ltd Metodo para identificar respondedores a degradantes de smarca2/4.
US20220396604A1 (en) 2019-10-25 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions comprising modified smarcb1 and uses thereof
EA202192101A1 (ru) 2019-11-21 2021-12-09 Фогхорн Терапьютикс Инк. Соединения и их применение
MX2022009309A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de los mismos.
WO2021155320A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
MX2022009308A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de estos.
US20230348452A1 (en) 2020-01-29 2023-11-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3166455A1 (en) 2020-01-29 2021-08-05 Neville John ANTHONY Heterocyclic compounds useful for modulating baf complexes
US20250283871A1 (en) 2020-03-13 2025-09-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CN115867314A (zh) 2020-05-20 2023-03-28 福宏治疗公司 治疗癌症的方法
US20240158387A1 (en) 2021-03-09 2024-05-16 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
JP2024511383A (ja) 2021-03-19 2024-03-13 フォグホーン セラピューティクス インコーポレイテッド Ｂｒｇ１及びｂｒｍの酵素活性の阻害剤の治療レジメン
EP4376886A4 (en) 2021-07-29 2025-05-14 Foghorn Therapeutics Inc. Methods of treating cancer
US20250339441A1 (en) 2022-04-08 2025-11-06 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196560A1 (en) 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer
EP4504210A2 (en) 2022-04-08 2025-02-12 Foghorn Therapeutics Inc. Methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation
CN218451564U (zh) 2022-08-09 2023-02-07 宁波立奇电器有限公司 一种双锅双风道式空气炸锅
WO2024086577A1 (en) 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases
WO2024216136A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for the treatment of hematological cancers
WO2024216151A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2024249769A2 (en) 2023-06-02 2024-12-05 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2025080769A1 (en) 2023-10-10 2025-04-17 Foghorn Therapeutics Inc. Methods of treating cancer
WO2025080767A1 (en) 2023-10-10 2025-04-17 Foghorn Therapeutics Inc. Differentiation and maintenance dosing regimen for fhd 286 (brg1/brm inhibitor)

Also Published As

Publication number Publication date
EP4096664A1 (en) 2022-12-07
MX2022009309A (es) 2022-08-22
PH12022551937A1 (en) 2023-10-23
AU2021213811A1 (en) 2022-07-28
TWI859406B (zh) 2024-10-21
CN115023226A (zh) 2022-09-06
CO2022010547A2 (es) 2022-09-09
WO2021155262A1 (en) 2021-08-05
EP4096664A4 (en) 2024-02-28
US12486262B2 (en) 2025-12-02
JP7561195B2 (ja) 2024-10-03
KR20220133258A (ko) 2022-10-04
TW202136252A (zh) 2021-10-01
US20230129003A1 (en) 2023-04-27
IL295100A (en) 2022-09-01
JP2023512039A (ja) 2023-03-23
US11485732B2 (en) 2022-11-01
BR112022015004A2 (pt) 2022-09-20
US20210230154A1 (en) 2021-07-29
US20240101550A1 (en) 2024-03-28
ZA202207804B (en) 2023-12-20
CA3167275A1 (en) 2021-08-05
UA129728C2 (uk) 2025-07-16

Similar Documents

Publication Publication Date Title
AR121226A1 (es) Compuestos y usos de estos
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR132338A1 (es) Inhibidores de ras
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
CL2021002903A1 (es) Inhibidores de cdk
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
CO2021008681A2 (es) Inhibidor de 15-pgdh
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
UY37941A (es) Derivados de bencimidazol y sus usos
CL2022001353A1 (es) Inhibidores de egfr
CO2022008719A2 (es) Compuestos para modular la actividad de fxr y usos de los mismos
CO2021017202A2 (es) Compuestos tricíclicos
DOP2025000009A (es) Inhibidores de acc novedosos
CL2024001298A1 (es) Compuestos de cd73
MX2020011367A (es) Compuesto oxo-sustituido.
AR042037A1 (es) Profarmaco de celecoxib
CO2022015205A2 (es) Procesos para la preparación de un inhibidor de cinasa
AR122372A1 (es) Compuestos y usos de estos
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
AR132601A1 (es) Derivados de piridopirimidina y usos de estos
AR134110A1 (es) Inhibidores de ras
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
AR128896A1 (es) Degradadores de ikzf2 y usos de estos